Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.
2016
Breast cancerremains a major public health problem worldwide. Chemotherapy serves an important role in the treatment of
breast cancer. However, resistance to chemotherapeutic agents, in particular, multi-drug resistance (MDR), is a major cause of treatment failure in cancer. Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of
breast cancer. Pristimerin, a quinonemethide
triterpenoidcompound isolated from
Celastraceaeand
Hippocrateaceae, has been shown to possess antitumor, anti-inflammatory, antioxidant and insecticidal properties. The aim of the present study was to investigate whether pristimerin can override chemoresistance in
MCF-7/adriamycin (ADR)-resistant human
breast cancercells. The results demonstrated that pristimerin indeed displayed potent cytocidal effect on multidrug-resistant
MCF-7/ADR
breast cancercells, and that these effects occurred through the suppression of Akt signaling, which in turn led to the downregulation of antiapoptotic effectors and increased apoptosis. These findings indicate that use of pristimerin may represent a potentially promising approach for the treatment of ADR-resistant
breast cancer.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
29
References
13
Citations
NaN
KQI